Product Information

ImprimisRx^® Product Information

ImprimisRx specializes in compounding customized medications to meet unique patient needs. As with all compounded medications, dosages may be customized to meet the individual needs of a patient. Only a prescribing physician may determine the appropriate use for their patient for an ImprimisRx compounded medication.

Compounded medications, made for the specific needs of a patient, are by their nature, not reviewed nor approved by the U.S. Food and Drug Administration (“FDA”).

All ImprimisRx facilities, where our compounded medications are produced, are inspected by FDA.

All active pharmaceutical ingredients contained in ImprimisRx’s compounded medications are obtained from FDA-registered entities.

When applicable, ImprimisRx compounded medications include components of FDA-approved drugs, as required under federal law.

ImprimisRx compounded medications may be ordered by a prescribing physician only when there is not a sufficient commercially available drug to meet a patient’s clinical need. Prescribing physicians may contact ImprimisRx’s pharmacists to discuss whether one of our compounded medications may be suitable for the clinical needs of a patient.

Regardless of a patient’s ability to afford an FDA-approved commercially available medication, FDA guidance prohibits ImprimisRx’s from copying any commercially available FDA-approved product.

ImprimisRx’s formulations are intended for professional use only.

Tri-Moxi+™ (Triamcinolone/Moxifloxacin) – Potential Ingredient Risks

(Triamcinolone acetonide 15mg and Moxifloxacin hydrochloride 1mg/mL)

May be customized.

Triamcinolone Acetonide
(9mg/0.6mL)

Moxifloxacin HCl
(0.6mg/0.6mL)

Possible Indications

Postoperative Ophthalmic Inflammation
Sympathetic Ophthalmia
Diffuse Posterior Uveitis
Allergic Corneal Margin Ulcer
Iritis and Keratitis
Optic Neuritis

Bacterial Conjunctivitis

Field Experience with Regards to
Temporary Visual Impairment

Following intraocular administration of Triamcinolone Acetonide Suspension, it has been reported that visual acuity and “floaters” can take several hours; up to 36 hours to clear and in rare cases, up to 48 hours. Because of the nature of a suspension, which includes particles suspended in a vehicle, it is likely to affect the visual field for a period of time and consequently, patients should be appropriately counseled prior to use. The patient is encouraged to sit upright for 6 hours.

Possible Adverse Effects

Anaphylactoid Shock
Blindness
Cataract
Corneal Perforation
Cortical Cataract
Conjunctival Hemorrhage
Eye Pain, Infection, Irritation Pruritus
Abnormal Sensation in Eyes
Abnormal Sensory Symptoms
Edema
Bleeding at Injection Site
Glaucoma
Hypertension
Hypopyon
Increased Intraocular Pressure
Increased Lacrimation
Vitreous Detachment
Vitreous Opacity
Wound Healing Impairment

Conjunctival Irritation
Fever
Eye Irritation
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Dyspnea
Facial Edema
Fungal Superinfection
Laryngeal Edema
Loss of Consciousness
Pharyngeal Edema
Pruritus
Superinfection
Urticaria
Pigment Dispersion Syndrome

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake well before use

Store upright in original vial

For professional use only

Vehicle

Surfacants: Polysorbate low concentration. Contains no poloxamer

Viscosity Modifier: Sodium Carboxymethylcellulose

Osmolality: Iso-osmolar

Dex-Moxi^® (Dexamethasone/Moxifloxacin) – Potential Ingredient Risks

(Dexamethasone 1mg and Moxifloxacin hydrochloride 5mg/mL)

May be customized.

Dexamethasone Sodium Phosphate
(1mg/mL)

Moxifloxacin HCl
(5mg/mL)

Possible Indications

Post-Surgical Inflammation
Allergic Conjunctivitis
Inflammation of Anterior Segment of Eye
Keratitis, Optic Neuritis, Iritis
Sympathetic Ophthalmia

Bacterial Conjunctivitis

Possible Adverse Effects

Conjunctival Irritation
Burning and Stinging Sensation
Fever
Eye Irritation and Infection
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Blindness
Post-Injection Flare
Wound Healing Suppression
Anaphylaxis
Corneal Perforation
Headache
Subcapsular Posterior Cataract
Ocular Hypertension
Optic Nerve Damage
Visual Field Defect

Potential Contraindications/Precautions

Infants and patients less than 12 years of age
Lactation
Pregnancy

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

For Professional use only

Dex-Moxi-Ketor^® (Dexamethasone/Moxifloxacin/Ketorolac) – Potential Ingredient Risks

(Dexamethasone 1mg, Moxifloxacin hydrochloride 0.5mg, and Ketorolac 0.4mg/mL)

May be customized.

Dexamethasone Sodium Phosphate
(1mg/mL)

Moxifloxacin HCl
(0.5mg/mL)

Ketorolac Tromethamine
(0.4mg/mL)

Possible Indications

Postoperative Inflammation
Allergic Conjunctivitis
Inflammation of Anterior Segment of Eye
Keratitis, Optic Neuritis, Iritis
Sympathetic Ophthalmia

Bacterial Conjunctivitis

Postoperative Eye Pain
Transient Burning and Stinging in the Eyes

Possible Adverse Effects

Burning Sensation of Eyes
Stinging of Eyes
Conjunctival Hyperemia
Corneal Edema
Corneal Erosion
Corneal Infiltrates
Corneal Perforation
Corneal Thinning
Eye Pain and Irritation
Headache
Hypercreativity Reaction
Iritis
Ocular Edema
Ophthalmic Inflammation
Superficial Eye Infection
Superficial Keratitis
Tissue Damage

Potential Contraindications/Precautions

Infants and patients less than
12 Years of age
Lactation
Pregnancy

Infants
Lactation
Pregnancy

Infants and patients less than
12 Years of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

For professional use only

Moxifloxacin HCl – Potential Ingredient Risks

(Moxifloxacin hydrochloride)

May be customized.

Moxifloxacin HCl

Possible Indications

Bacterial Conjunctivitis

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle.
Protect from light.
For professional use only.

Epi-Lido (Lidocaine hydrochloride/Epinephrine in BSS) PF/SF – Potential Ingredient Risks

(Lidocaine hydrochloride/Epinephrine in BSS (PF/SF) 0.75/0.025%)

May be customized.

Epinephrine HCl
(0.025%)

Lidocaine HCl
(0.75%)

Possible Indications

Intraoperative Mydriasis
Open-Angle Glaucoma
Hemorrhage During Ocular Surgery

Ocular Anesthesia

Possible Adverse Effects

Increased Intraocular pressure
Hypertension

Conjunctival Hyperemia
Corneal Epithelial Changes
Headache

Potential Contraindications/Precautions

Lactation
Pregnancy

Infants
Lactation
Pregnancy

Storage

Store frozen until use

(-10°C to -25°C)

Auxillary Labeling

Do not Refreeze

Store upright in original bottles. Protect from light. For professional use only.

Phenyl-Lido (Phenylephrine hydrochloride/Lidocaine hydrochloride) PF/SF – Potential Ingredient Risks

(Phenylephrine hydrochloride/Lidocaine hydrochloride (PF/SF) 1.5/1%)

May be customized.

Phenylephrine HCl
(1.5%)

Lidocaine HCl
(1%)

Possible Indications

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Ocular Anesthesia

Possible Adverse Effects

Increased Intraocular pressure
Hypertension

Conjunctival Hyperemia
Corneal Epithelial Changes
Headache

Potential Contraindications/Precautions

Lactation
Pregnancy

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

For professional use only.

Mydriatic 2 (Tropicamide/Phenylephrine) – Potential Ingredient Risks

(Tropicamide/Phenylephrine hydrochloride, 1/2.5%)

May be customized.

Tropicamide
(1%)

Phenylephrine HCl
(2.5%)

Possible Indications

Cycloplegia
Mydriasis

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Possible Adverse Effects

Blurred Vision
Cardiorespiratory Arrest
Headache
Hypersensitivity Reaction
Increased Intraocular Pressure
Muscle Rigidity
Nausea
Pallor
Photophobia
Psychotic Reaction
Superficial Punctate Keratitis
Tachycardia
Transient Burning or Stinging in the Eyes
Vomiting
Xerostomia

Acute Keratitis
Acute Myocardial Infarction
Allergic Conjunctivitis
Blurred Vision
Dermatitis
Diaphoresis
Dizziness
Eye Irritation
Headache
Hypertension
Lacrimation
Pallor
Photophobia
Pigment Granules Liberation from the Iris
Subarachnoid Hemorrhage
Syncope
Tachycardia
Tremor

Potential Contraindications/Precautions

Patients less than 12 years of age
Lactation
Pregnancy

Neonates and patients less than 12 years of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

For professional use only.

Mydriatic 3* (Tropicamide/Cyclopentolate/Phenylephrine) – Potential Ingredient Risks

(Tropicamide 1%, Cyclopentolate 1%, and Phenylephrine hydrochloride 2.5%)

May be customized.

Tropicamide
(1%)

Cyclopentolate
(1%)

Phenylephrine HCl
(2.5%)

Possible Indications

Cycloplegia
Mydriasis

Cycloplegia
Mydriasis
Posterior Synechiae
Uveitis

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Possible Adverse Effects

Blurred Vision
Burning Sensation
Coma
Death
Disorientation
Dry Secretions
Eye Irritation
Hallucination
Hyperactive Behavior
Hyperpyrexia
Hypertension
Hyperhidrosis
Increased Intraocular Pressure
Photophobia
Psychotic Reaction
Restlessness
Seizure
Superficial Punctate Keratitis
Tachycardia
Urinary Retention
Vasodilation
Xerostomia

Potential Contraindications/Precautions

Patients less than 12 years of age
Lactation
Pregnancy

Infants

Neonates and patients less than 12 years of age
Lactation
Pregnancy

Storage

Store under room temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

For professional use only

Mydriatic 4*(Tropicamide/Proparacaine/Phenylephrine/Ketorolac) – Potential Ingredient Risks

(Tropicamide 1%, Proparacaine 0.5%, Phenylephrine 2.5%, and Ketorolac 0.5%)

May be customized.

Tropicamide
(1%)

Proparacaine HCl
(0.5%)

Phenylephrine HCl
(2.5%)

Ketorolac Tromethamine
(0.5%)

Possible Indications

Cycloplegia
Mydriasis

Ocular Anesthesia

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Cystoid Macular Edema
Miosis
Postoperative Eye Pain
Postoperative Ophthalmic Inflammation
Seasonal Allergic Conjunctivitis
Transient Burning or Stinging in the Eyes

Possible Adverse Effects

Blurred Vision
Stinging of the Eyes
Hypersensitivity Reaction

Burning Sensation of Eyes
Stinging of Eyes
Eye Irritation
Hypersensitivity
Pruritus and Skin Rash
Superficial Keratitis
Superficial Bacterial Eye Infection
Conjunctival Hyperemia
Corneal Edema
Corneal Erosion
Corneal Infiltrates
Corneal Perforation
Corneal Thinning
Eye Pain
Headache
Iritis
Ocular Edema
Superficial Keratitis
Tissue Damage

Potential Contraindications/

Precautions

Patients less than 12 Years of age
Lactation
Pregnancy

Infants
Lactation
Pregnancy

Neonates and patients less than
12 years of age
Lactation
Pregnancy

Patients less than 3 years of age
Lactation
Pregnancy
Child bearing aged females

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Protect from light

For professional use only

MKO Melt^® (Midazolam, Ketamine HCl, Ondansetron) – Potential Ingredient Risks

(Midazolam 3mg, Ketamine HCl 25mg, Ondansetron 2mg)

May be customized.

Midazolam
(3mg)

Ketamine HCl
(25mg)

Ondansetron
(2mg)

Possible Indications

Surgical Sedation
Amnesia
Anxiety

Surgical Anesthesia
Induction of General Anesthesia

Postoperative Nausea and Vomiting
Cancer Chemotherapy-Induced Nausea and Vomiting

Possible Adverse Effects

Hypoxemia
Nausea and Vomiting
Agitation
Airway Obstruction
Bradycardia
Hypoxia
Laryngospasm
Respiratory Depression
Rhonchi
Sedation
Skin Rach
Cardia Arrest
Respiratory Arrest

Airway Obstruction
Anaphylaxis
Anxiety
Apnea
Bradycardia
Cardia Arrhythmia
Confusion
Disorientation
Dysphoria
Hallucination
Hypotension
Insomnia
Nausea
Nystagmus
Psychotic Reaction
Respiratory Depression
Skin Rash
Tonic Clonic Epilepsy
Vomiting

Headache and Malaise
Sedation
Wound Healing Impairment
Anxiety
Bradycardia
Constipation
Diarrhea
Dizziness
Fever
Gynecologic Disease
Hypotension
Hypoxia
Pruritus
Shivering
Urinary Retention
Skin Rach
Anaphylaxis
Chest Pain
Dyspnea
Laryngeal Edema

Potential Contraindications/Precautions

Infants less than 6 months of age
Lactation
Pregnancy

Lactation
Pregnancy

Infants less than 6 months of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

For professional use only

Lat* (Latanoprost) PF – Potential Ingredient Risks

(Latanoprost 0.005%)

May be customized.

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma

Possible Adverse Effects

Iris pigmentation changes
Eyelid skin darkening
Eyelash changes (increased length, thickness,
pigmentation and number of lashes)
Iritis/uveitis
Macular edema, including cystoid macular
edema
Foreign body sensation
Punctate keratitis
Stinging
Conjunctival hyperemia
Blurred vision
Itching
Burning
Increased pigmentation of the iris
Excessive tearing
Eyelid discomfort/pain
Dry eye
Eye pain
Eyelid margin crusting

Erythema of the eye lid

Photophobia

Potential Contraindications/Precautions

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration.
2°C to 8°C (36°F to 46°F)
Protect from light.

Auxillary Labeling

For professional use only.
Store upright in original bottle.

Dor (Dorzolamide PF) – Potential Ingredient Risks

(Dorzolamide 2%)

May be customized

Dorzolamide
(2%)

Possible Indications

Treatment of elevated intraocular

pressure in patients with ocular

hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning, stinging, or discomfort

immediately following ocular administration

Bitter taste

Superficial punctate keratitis

Ocular allergic reaction

Conjunctivitis and lid reactions

Blurred vision

Eye redness

Tearing

Dryness

Photophobia

Headache

Nausea

Asthenia/fatigue

Skin rashes

Urolithiasis

Iridocyclitis

Potential Contraindications/Precautions

Neonates and Patients Less than 12 Years

Lactation

Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

For professional use only

Store upright in original bottle

Protect from light

Brim-Dor^®* (Brimonidine Tartrate, Dorzolamide) PF – Potential Ingredient Risks

(Brimonidine Tartrate 0.15%, Dorzolamide 2%)

May be customized. customized.

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Oral dryness
Ocular hyperemia,
Burning and Stinging on Instillation
Headache
Blurred vision
Foreign body sensation
Fatigue/drowsiness
Conjunctival follicles
Ocular allergic reactions
Ocular pruritis
Corneal staining/erosion
Photophobia
Eyelid erythema
Ocular ache/pain
Upper respiratory symptoms
Dizziness
Blepharitis, ocular irritation
Lid crusting
Conjunctival hemorrhaging
Abnormal taste, insomnia, depression,
hypertension, anxiety, palpitations/
arrhythmias, nasal dryness and syncope

Ocular burning, stinging, or discomfort
immediately following ocular administration
Bitter taste
Superficial punctate keratitis
Ocular allergic reaction
Conjunctivitis and lid reactions
Blurred vision
Eye redness
Tearing
Dryness
Photophobia
Headache
Nausea
Asthenia/fatigue
Skin rashes
Urolithiasis
Iridocyclitis

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle.

Protect from light.

Tim-Lat^®* (Timolol Maleate, Latanoprost) PF – Potential Ingredient Risks

(Timolol Maleate 0.5%, Latanoprost 0.005%)

May be customized. customized.

Timolol Maleate
(0.5%)

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular
accident, cerebral ischemia, cardiac failure and
cardiac arrest

Potential Contraindications/Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration.
Protect from light.

2°C to 8°C (36°F to 46°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle.

Tim-Dor-Lat^®* (Timolol Maleate, Dorzolamide, Latanoprost) PF – Potential Ingredient Risks

(Timolol Maleate 0.5%, Dorzolamide 2%, and Latanoprost 0.005%)

May be customized.

Timolol Maleate
(0.5%)

Dorzolamide
(2%)

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Potential Contraindications/Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration

2°C to 8°C (36°F to 46°F)

Protect from light.

Auxillary Labeling

For professional use only.

Store upright in original bottle

Tim-Brim-Dor^®* (Timolol Maleate, Brimonidine Tartrate, Dorzolamide) PF – Potential Ingredient Risks

(Timolol Maleate 0.5%, Brimonidine Tartrate 0.15%, and Dorzolamide 2%)

May be customized.

Timolol Maleate
(0.5%)

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Potential Contraindications/Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Storage

Store at room temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle

Protect from light.

Tim-Brim-Dor-Lat^®* (Timolol Maleate, Brimonidine Tartrate, Dorzolamide, Latanoprost) PF – Potential Ingredient Risks

(Timolol Maleate 0.5%, Brimonidine Tartrate 0.15%, Dorzolamide 2%, Latanoprost 0.005%) PF

May be customized.

Timolol Maleate
(0.5%)

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular accident,
cerebral ischemia, cardiac failure and cardiac arrest

Potential Contraindications/

Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration

2°C to 8°C (36°F to 46°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle

Protect from light

Tim-Brim-Dor-Bim* (Timolol Maleate, Brimonidine Tartrate, Dorzolamide, Bimatoprost) PF – Potential Ingredient Risks

(Timolol Maleate 0.5%, Brimonidine Tartrate 0.15%, Dorzolamide 2%, Bimatoprost 0.01%) PF

May be customized.

Timolol Maleate
(0.5%)

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Bimatoprost
(0.01%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular accident,
cerebral ischemia, cardiac failure, and cardiac arrest

Conjunctival hyperemia
Blurred vision
Itching
Burning
Increased pigmentation of the iris
Excessive tearing
Eyelid discomfort/pain
Dry eye
Eye pain
Eyelid margin crusting
Erythema of the eye lid
Photophobia

Potential Contraindications/

Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Patients Less than 16 Years
Lactation
Pregnancy
Child-Bearing Aged Females

Storage

Store at room temperature

20° to 25°C (68° to 77°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle

Protect from light

Moxi-Brom (Moxifloxacin/Bromfenac) – Potential Ingredient Risks

(Moxifloxacin hydrochloride and Bromfenac)

May be customized.

Moxifloxacin HCl

Bromfenac Sodium Sesquihydrate

Possible Indications

one_third]

Bacterial Conjunctivitis

[/one_third]

Postoperative Ophthalmic Inflammation

Postoperative Ophthalmic Pain

Possible Adverse Effects

Conjunctival Irritation

Decreased Visual Acuity

Dysgeusia

Eye Discharge

Eye Irritation

Eye Pain

Eye Redness

Eyelid Edema

Headache

Increased Lacrimation

Keratitis

Papillary Conjunctivitis

Pyrexia

Subconjunctival Hemorrhage

Tearing

Hypersensitivity Reaction

Abnormal Sensation in Eyes

Anaphylaxis

Anterior Chamber Eye Hemorrhage

Burning Sensation

Conjunctival Hyperemia

Corneal Erosion

Corneal Perforation

Corneal Thinning

Corneal Ulcer

Epithelial Keratopathy

Eye Irritation

Eye Pain

Eye Pruritus

Eye Redness

Headache

Hypersensitivity Reaction

Iritis

Keratitis

Prolonged Bleeding

Stringing Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Lactation

Pregnancy

Pediatric Patients

Corneal Disease

Thrombocytopenia

Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Pred-Gati-Brom^®* Suspension (Prednisolone Acetate, Gatifloxacin, Bromfenac) – Potential Ingredient Risks

(Prednisolone Acetate 1%, Gatifloxacin 0.5%, Bromfenac 0.075%)

May be customized.

Prednisolone Acetate
(1%)

Gatifloxacin
(0.5%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis

Abnormal Sensation in Eyes
Anaphylaxis
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

Pred-Gati-Brom^®* Solution (Prednisolone Phosphate, Gatifloxacin, Bromfenac) – Potential Ingredient Risks

(Prednisolone Phosphate 1%, Gatifloxacin 0.5%, Bromfenac 0.075%)

May be customized.

Prednisolone Phosphate
(1%)

Gatifloxacin
(0.5%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Burning or Stinging Sensation
Accommodation Disturbance
Conjunctival Hyperemia
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Subscapular Posterior Cataract
Visual Field Defect
Wound Healing Impairment
Corneal Ulcer
Viral Infection

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

Pred-Moxi-Brom (Prednisolone Acetate, Moxifloxacin, Bromfenac) – Potential Ingredient Risks

(Prednisolone Acetate1%, Moxifloxacin 0.5%, Bromfenac 0.075%)

May be customized.

Prednisolone Acetate
(1%)

Moxifloxacin
(0.075%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic

Inflammation

Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Ophthalmic Pain

Possible Adverse Effects

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis
Pyrexia
Subconjunctival Hemorrhage
Tearing
Hypersensitivity Reaction

Abnormal Sensation in Eyes
Increased Intraocular Pressure
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia (bleeding disorders)

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Store upright in original bottle.

Protect from light.

Pred-Moxi-Nepaf^® (Prednisolone Acetate, Moxifloxacin, Nepafenac) – Potential Ingredient Risks

(Prednisolone Acetate 1%, Moxifloxacin 0.5%, Nepafenac 0.1%)

May be customized.

Prednisolone Acetate
(1%)

Moxifloxacin
(0.5%)

Nepafenac
(0.1%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia (bleeding disorders)

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Store upright in original bottle.

Protect from light.

Pred-Moxi^® (Prednisolone Acetate, Moxifloxacin) – Potential Ingredient Risks

(Prednisolone Acetate 1%, and Moxifloxacin 0.5%)

May be customized.

Prednisolone Acetate
(1%)

Moxifloxacin
(0.5%)

Possible Indications

Postoperative Ophthalmic
Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Store upright in original bottle

Pred-Brom (Prednisolone Acetate, Bromfenac) – Potential Ingredient Risks

(Prednisolone acetate 1%, and moxifloxacin 0.075%)

May be customized.

Prednisolone Acetate
(1%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation

Postoperative Ophthalmic Pain

Possible Adverse Effects

Accommodation Disturbance

Anterior Uveitis

Blepharitis

Conjunctival Hyperemia

Conjunctivitis

Corneal Perforation or Ulcer

Decreased Visual Acuity

Eye Infection

Glaucoma

Increased Intraocular Pressure

Keratitis

Mydriasis

Optic Nerve Damage

Visual Field Defect

Wound Healing Impairment

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake well before use

Store upright in original bottle

Pred-Brom^®* (Prednisolone Phosphate, Bromfenac) – Potential Ingredient Risks

(Prednisolone Phosphate 1%, and Bromfenac 0.075%)

May be customized.

Prednisolone Phosphate
(1%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Postoperative Ophthalmic Inflammation
Postoperative Ophthalmic Pain

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light.

Store upright in original bottle

Pred-Nepaf^® (Prednisolone Acetate, Nepafenac) – Potential Ingredient Risks

(Prednisolone Acetate 1%, and Nepafenac 0.01%)

May be customized.

Prednisolone Acetate
(1%)

Nepafenac
(0.01%)

Possible Indications

Postoperative Ophthalmic
Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Prednisolone Acetate – Potential Ingredient Risks

(Prednisolone Acetate 1%)

May be customized.

Prednisolone Acetate
(1%)

Possible Indications

Postoperative Inflammation
Blepharitis
Allergic Conjunctivitis
Catarrhal Corneal Ulcer
Conjunctival Infection
Corneal Injury
Keratoconjunctivitis
Superficial Keratitis
Vernal Conjunctivitis

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle
Shake well before use

Protect from light.

Moxi-Brom (Moxifloxacin/Bromfenac) – Potential Ingredient Risks

(Moxifloxacin hydrochloride 0.5% and Bromfenac sodium sesquihydrate 0.075%)

May be customized.e customized.

Moxifloxacin HCL
(0.5%)

Bromfenac Sodium Sesquihydrate
(0.075%)

Possible Indications

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Ophthalmic Pain

Possible Adverse Effects

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Lactation
Pregnancy
Pediatric Patients
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Atropine Sulfate Ophthalmic Solution* – Potential Ingredient Risks

(Atropine Sulfate Ophthalmic Solution 0.01%)

May be customized.

Atropine Sulfate Ophthalmic Solution
(0.01%)

Possible Indications

Widen pupil before an eye exam or eye surgery
Treat eye swelling
Treat amblyopia (lazy eye)
Treat myopia (nearsightedness)

Possible Adverse Effects

Blurred vision
Visual Disturbance
Light sensitivity
Eye stinging, irritation, eye pain
Fast heartbeat
Heartbeat that does not feel normal
Flushing
Restlessness
Feeling irritable
Dry mouth
Dry skin

Potential Contraindications/Precautions

Do not give to children less than 3 months of age
Patients 65 years of age or older, use this preparation with care.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity (Glycerin Ophthalmic Solution) PF – Potential Ingredient Risks

(Glycerin 1%)

May be customized.

Glycerin
(1%)

Possible Indications

Ophthalmic lubricant; for temporary
relief of burning and eye irritation due to
dry eyes

Possible Adverse Effects

Blurred vision
Crusting of eyelid
Stinging of eyes (mild)

Potential Contraindications/Precautions

Self-medication:
When used for self-medication,
stop use and contact healthcare provider
if changes in vision, eye pain, continued
redness or irritation occur, or if the condition
worsens or persists for more than 72 hours.
To avoid contamination, do not touch tip of
container to any surface. Replace cap after
using. Do not use if solution is cloudy or
changes color.

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-A* (Azithromycin Ophthalmic Solution) – Potential Ingredient Risks

(Azithromycin Ophthalmic Solution 1%)

May be customized.

Azithromycin Ophthalmic Solution
(1%)

Possible Indications

Bacterial conjunctivitis caused by susceptible bacteria

Possible Adverse Effects

Eye irritation
Blurred vision
Contact dermatitis
Corneal erosion
Decreased visual acuity,
Dysgeusia
Eye pain
Facial edema
Eye reactions: burning sensation, eye discharge, stinging)
Nasal congestion,
Sinusitis
Swelling of the eye
Skin rash

Potential Contraindications/Precautions

Hypersensitivity to Azithromycin or any component of the formulation.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-B* (Betamethasone Sodium Phosphate Ophthalmic Solution) – Potential Ingredient Risks

(Betamethasone Sodium Phosphate Ophthalmic Solution 0.1%)

May be customized.

Betamethasone Sodium Phosphate Ophthalmic Solution
(0.1%)

Possible Indications

Treat eye irritation
Treat eye swelling

Possible Adverse Effects

Headache
Eye burning, irritation, itching
Dry eyes
Blurred eyesight
Feeling that something is in the eye
Runny nose
Sore throat
Light sensitivity
Cataracts or glaucoma with chronic use
Corneal erosion

Potential Contraindications/Precautions

Infants and children under the age of 18.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-C Drops^® (Cyclosporine ophthalmic emulsion) PF – Potential Ingredient Risks

(Cyclosporine ophthalmic emulsion 0.1%)

May be customized.

Cyclosporine ophthalmic emulsion
(0.1%)

Possible Indications

Keratoconjunctivitis Sicca

Possible Adverse Effects

Blurred Vision
Conjunctival Hyperemia
Epiphora
Eye Discharge
Eye Pain
Foreign Body Sensation
Hypersensitivity
Pruritus
Stinging of the eyes
Swelling of the Eyes
Burning Sensation
Urticaria
Visual Disturbance

Potential Contraindications/Precautions

Infants and patients less than 16 years of age
Lactation

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-L* (Loteprednol Etabonate Ophthalmic Suspension) – Potential Ingredient Risks

(Loteprednol Etabonate Ophthalmic Suspension 0.5%)

May be customized.

Loteprednol Etabonate Ophthalmic Suspension
(0.5%)

Possible Indications

Treat eye irritation
Treat eye swelling
Treat eye pain after surgery

Possible Adverse Effects

Headache
Eye burning, irritation, itching
Dry eyes
Blurred eyesight
Feeling that something is in the eye
Runny nose
Sore throat
Light sensitivity
Cataracts or glaucoma with chronic use

Potential Contraindications/Precautions

Infants and children under the age of 18.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake well before use.
Store upright in original bottle.

Klarity-CL Drops* (Cyclosporine / Loteprednol Etabonate Ophthalmic Suspension PF) – Potential Ingredient Risks

(Cyclosporine 0.1% / Loteprednol Etabonate 0.2% Ophthalmic Suspension PF)

May be customized.

Cyclosporine / Loteprednol Etabonate Ophthalmic Suspension PF
(0.1%/0.2%)

Possible Indications

Keratoconjunctivitis Sicca
Treat eye irritation
Treat eye swelling
Treat eye pain after surgery

Possible Adverse Effects

Blurred Vision
Conjunctival Hyperemia
Epiphora
Eye Discharge
Eye Pain
Headache
Foreign Body Sensation
Hypersensitivity
Pruritus
Stinging of the eyes
Swelling of the eyes
Burning Sensation
Dry eyes
Blurred eyesight
Runny nose
Urticaria
Visual Disturbance
Sore throat
Light sensitivity
Cataracts or glaucoma with chronic use

Potential Contraindications/Precautions

Infants and children under the age of 16.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake well before use.
Store upright in original bottle.

Ascorbic Acid – Potential Ingredient Risks

(Ascorbic Acid 500mg/ml)

May be customized.

Ascorbic Acid
(500mg/ml)

Possible Indications

Prevention and treatment of scurvy
Treatment of symptoms of mild deficiency

Possible Adverse Effects

Hyperoxaluria (with large doses)
Diarrhea
Dizziness
Fatigue
Flank pain
Flushing
Headache
Heartburn
Nausea
Vomiting

Potential Contraindications/Precautions

Oxalate nephropathy/nephrolithiasis; elderly patients and pediatric patients <2 years of age may be at increased risk. Patients with diabetes mellitus should not take excessive doses for extended periods of time. Hemolysis has been reported in patients with glucose-6-phosphatase dehydrogenase (G6PD) deficiency and the risk for severe hemolysis may be increased during ascorbic acid therapy. Use with caution in patients with hemochromatosis. Use with caution in patients with renal impairment or patients prone to recurrent renal calculi; may have increased risk of developing acute or chronic oxalate nephropathy. Elderly and Pediatric: Use with caution in the elderly and children <2; may be at increased risk for oxalate nephropathy.

Storage

Store at Room Temperature 20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Keep all medicines out of the reach of children. Minimize exposure to light because Ascorbic Acid solution is light sensitive. This Vial is a single dose preservative free vial. Discard unused portion. Throw away any medicine after the beyond use date.

Dexpanthenol MDV* – Potential Ingredient Risks

(Dexpanthenol MDV 250mg/ml)

May be customized.

Dexpanthenol MDV
(250mg/ml)

Possible Indications

Is a sterile, nonpyrogenic, aqueous solution indicated for prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus.

Possible Adverse Effects

There have been a few reports of allergic reactions and single reports of several other adverse events in association with the administration of Dexpanthenol. A causal relationship is uncertain. One patient experienced itching, tingling, di_culty in breathing. Another patient had red patches of skin. Two patients had generalized dermatitis and one patient urticaria. One patient experienced temporary respiratory di_culty following administration of Dexpanthenol injection 5 minutes after succinylcholine was discontinued. One patient experienced a noticeable but slight drop in blood pressure after administration of Dexpanthenol while in the recovery room. One patient experienced intestinal colic one-half hour after the drug was administered. Two patients vomited following administration and two patients had diarrhea 10 days post-surgery and after Dexpanthenol Injection. One elderly patient became agitated after administration of the drug.

Potential Contraindications/Precautions

If any signs of a hypersensitivity reaction appear, Dexpanthenol Injection should be discontinued. If ileus is a secondary consequence of mechanical obstruction, primary attention should be directed to the obstruction. The management of adynamic ileus includes the correction of any fluid and electrolyte imbalance (especially hypokalemia), anemia and hypoproteinemia, treatment of infection, avoidance where possible of drugs which are known to decrease gastrointestinal motility and decompression of the gastrointestinal tract when considerably distended by nasogastric suction or use of a long intestinal tube.

Storage

Store at Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

Auxillary Labeling

There have been rare instances of allergic reactions of unknown cause during the concomitant use of Dexpanthenol Injection with drugs such as antibiotics, narcotics and barbiturates. Dexpanthenol Injection should not be administered within one hour of succinylcholine.

DMPS* (Dimercaptopropane-1-sulfonic acid) – Potential Ingredient Risks

(Dimercaptopropane-1-sulfonic acid 50mg/ml)

May be customized.

Dimercaptopropane-1-sulfonic acid
(50mg/ml)

Possible Indications

Heavy Metal chelator including Lead, Mercury,
Arsenic and Cadmium.

Possible Adverse Effects

Nausea
Headaches
Changes in taste
Will make urine smell very sulfurous

Potential Contraindications/Precautions

Consult your physician and pharmacist with
a list of all your medications and allergies.
Do not take DMPS if you are pregnant or
plan to become pregnant or if you are
breast-feeding. Do not take DMPS if allergic
to DMPS or similar compounds.

Storage

Store in a refrigerator between 36°F to 46°F
(2°C to 8°C)

Auxillary Labeling

Keep this and all other medications away
from children and pets.

Edetate Disodium* 150mg/mL – Potential Ingredient Risks

(Edetate Disodium 150mg/mL)

May be customized.

Edetate Disodium
(150mg/ml)

Possible Indications

Emergency treatment of hypercalcemia and for the control of ventricular arrhythmias associated with digitalis toxicity.

Possible Adverse Effects

Abdominal cramps, nausea, vomiting, diarrhea, paresthesia, numbness, headache, low blood pressure, thrombophlebitis, febrile reactions, hyperuricemia, anemia, exfoliative dermatitis and other toxic skin and mucous membrane reactions, nephrotoxicity and damage to the reticuloendothelial system with hemorrhagic tendencies.

Potential Contraindications/Precautions

Pregnancy and breastfeeding
Asthma
Heart rhythm problems
Diabetes
Hypocalcemia
Hypokalemia
Hypomagnesemia
Liver problems and hepatitis
Kidney problems
Seizures
Tuberculosis

Storage

Store at 25°C (77°F) with excursions permitted between 15° to 30°C (59° to 86°F).

Auxillary Labeling

Protect from light.

Glutathione* – Potential Ingredient Risks

(Glutathione 200mg/ml)

May be customized.

Glutathione
(200mg/ml)

Possible Indications

In vitro studies and animal experiments have
shown that: Glutathione protects against DNA
damage and demonstrates a protective role
against carcinogens through inactivation
Stimulate the immune function improved
sperm motility and morphology in men.

Possible Adverse Effects

Increased flatulence
Loose stools
Flushing
Weight gain
Reversible, severe hepatic injury in high doses

Potential Contraindications/Precautions

Information regarding safety and efficacy in
pregnancy and lactation is lacking.

Storage

Store in a refrigerator between 36°F to 46°F
(2°C to 8°C)

Auxillary Labeling

Throw away any unused medicine after the
beyond use date. Do not flush unused
medications or pour down a sink or drain.

Methylcobalamin* – Potential Ingredient Risks

(Methylcobalamin)

May be customized.

Methylcobalamin

Possible Indications

Vitamin B12 deficiency
Pernicious anemia
Neuropathy; regeneration of motor neurons

Possible Adverse Effects

Anorexia
Nausea
Vomiting
Diarrhea
Headache

Potential Contraindications/Precautions

Patients with early hereditary optic nerve
atrophy, cyanocobalamin hypersensitivity,
and those who are pregnant. Your health
care provider needs to know if you have any
of these conditions: kidney disease; Leber’s
disease; megaloblastic anemia; an unusual
or allergic reaction to methylcobalamin,
cobalt, other medicines, foods, dyes, or
preservatives; pregnant or trying to get
pregnant; breast-feeding.

Storage

Store in a refrigerator between 36°F to 46°F
(2°C to 8°C). Protect from light.

Auxillary Labeling

Keep all medicine out of the reach of
children and pets. Throw away any unused
medicine after the beyond use date. Do not
flush unused medications or pour down a
sink or drain.

MIC/Carnitine* – (Methionine, Inositol, Choline Chloride, Carnitine) – Potential Ingredient Risks

(Methionine, Inositol, Choline Chloride, Carnitine 25/50/50/50mg/ml)

May be customized.

Methionine
(25mg/ml)

Inositol
(50mg/ml)

Choline Chloride
(50mg/ml)

Carnitine
(50mg/ml)

Possible Indications

Helps the liver maintain the optimal ability to process fatty acids

Aids in the transport of fat into and out of the liver and intestinal cells, acts synergistically with choline, exhibiting more lipotropic activity than when administered alone.

Stimulates the mobilization of fatty acids and prevents their deposition in a given part of the body.

Parenterally for prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing dialysis.

Possible Adverse Effects

Pain at injection site
Flushing

Pain at injection site

Pain at injection site
Diarrhea
Nausea
Vomiting
Abdominal cramps
Change in body odor
Abdominal pain
Injection site irritation
Cough
Runny nose
Lack of appetite
Weight gain
Weight loss
Change in taste

Potential Contraindications/
Precautions

Do not take if you have an allergy to methionine or any part of this medicine. Tell your healthcare provider if you are allergic to any medicine. This includes rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other symptoms involved. Information regarding safety and efficacy in pregnancy and lactation is lacking.

Do not take if you have an allergy to inositol or any part of this medicine

Do not take if you have an allergy to Carnitineor any part of this medicine. Distributed into milk in cows; not known whether levocarnitine distributes into human milk. Consider discontinuance of nursing or the drug. Dosage of levocarnitine in pediatric patients under 18 years of age was based on specific patient case record observations rather than on studies that specifically defined age by protocol.

Storage

Store at Room Temperature 20°C to 25°C (68°F to 77°F). Refrigerate after opening.

Auxillary Labeling

Keep all medicine out of the reach of children and pets.

Nicotinamide Adenine Dinucleotide (NAD+)– Potential Ingredient Risks

(Nicotinamide Adenine Dinucleotide 100mg/ml)

May be customized.

Nicotinamide Adenine Dinucleotide
(1mg/mL)

Possible Indications

Cellular DNA repair and telomere maintenance. Useful in Alcohol and Drug Withdrawal, improvement in depression and chronic fatigue

Possible Adverse Effects

Headache
Shortness of Breath
Constipation
Decreased levels of gamma glutamyl transferase
Lactate dehydrogenase and aspartate aminotransferase
Hypersensitivity reaction

Potential Contraindications/Precautions

No known contraindications at this writing. Precautions are indicated with infusion rate which may lead to adverse effects, use slow IV rate

Storage

Store in a freezer at frozen temperature -25°C to -10°C (-13°F to 14°F). Protect from light

Auxillary Labeling

Keep all medicine out of the reach of children and pets. This vial is a single dose, preservative free vial. Discard any unused portion. Appropriately discard any medicine after the beyond use date. Do not flush medicines down the toilet.

Pyridoxal-5-Phosphate* – Potential Ingredient Risks

(Pyridoxal-5-Phosphate)

May be customized.

Pyridoxal-5-Phosphate
(100mg/ml)

Possible Indications

Treatment and prevention of pyridoxine (vitamin B6) deficiency

Possible Adverse Effects

Ataxia
Drowsiness
Headache
Neuropathy paresthesia
Seizure (following very large IV doses)
Acidosis
Folate deficiency
Nausea
Increased serum AST
Hypersensitivity reaction

Potential Contraindications/Precautions

Hypersensitivity to pyridoxal-5-phosphate or any component of the formulation Neuropathy: Severe, permanent peripheral neuropathies have been reported in long term use.

Storage

Store at Room Temperature 20°C to 25°C (68°F to 77°F). Protect from light.

Auxillary Labeling

Keep all medicine out of the reach of children and pets.

Taurine (L) MDV* 50mg/mL – Potential Ingredient Risks

(Taurine (L) MDV 50/mL)

May be customized.

Taurine (L) MDV
(50mg/ml)

Possible Indications

Taurine is indicated in those with congestive heart failure (CHF), liver disease (hepatitis), retinal disorder, chemotherapy side effects, cirrhosis, cystic fibrosis, diabetes, fatigue, high blood pressure, mental performance, insomnia, psychosis and anemia.

Possible Adverse Effects

No noted side effects when dosed within normal limits.

Potential Contraindications/Precautions

Recommended dosage if taurine is less than 3,000 mg/day. Dosage is different for each treatment. Several mediations may cause interactions with Taurine. Lithium may have a diuretic effect, Antiplatelets/ Anticoagulants may lower the clotting effect leading to bleeding, NSAIDs / Salicylates may lead to changed clotting times and bleeding.

Storage

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

Vitamin B – Complex with Hydroxocobalamin* – (Niacinamide/ Pyridoxine HCL/ Riboflavin-5-Phosphate/Thiamine HCL/ Panthenol/ Hydroxocobalamin) – Potential Ingredient Risks

(Niacinamide/ Pyridoxine HCL/ Riboflavin-5-Phosphate/Thiamine HCL)
(B complex with 1mg/ml)

May be customized.

Niacinamide

Pyridoxine HCL

Riboflavin-5-Phosphate

Thiamine HCL

Possible Indications

In disorders requiring parenteral administration of vitamins. Gastrointestinal disorders interfering with intake or absorption of vitamins. B vitamins Deficiencies

Used to prevent and to treat vitamin B6 deficiency

Used to prevent riboflavin deficiency and to treat ariboflavinosis

Treatment of thiamine deficiency syndromes

Possible Adverse Effects

Niacinamide may enhance the adverse/toxic effect of HMG-CoA Reductase. Inhibitors (Statins). Mild transient diarrhea Polycythemia vera, Peripheral vascular thrombosis. Itching transitory exanthema. Feeling of swelling of entire body. Anaphylactic shock and death.

Feelings of warmth
Pruritus
Urticaria
Weakness
Sweating
Nausea
Restlessness
Angioedema
Tightness in the throat
Cyanosis
Pulmonary edema
GI bleeding reported with parenteral administration.

Potential Contraindications/
Precautions

Sensitivity to the niacinamide.
No specific information for use in elderly.

Pyridoxine should not be used in patients with a history of sensitivity to the vitamin. According to one manufacturer, pyridoxine should not be administered IV to patients with heart disease. Pyridoxine hydrochloride reverses the therapeutic effects of levodopa, Carbidopa, Phenobarbital and Phenytoin.

Anaphylactogenesis may occur with parenteral thiamine. Use with caution. An intradermal test dose is recommended prior to administration in patients suspected of being sensitive to the drug

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)
Protect from light

Auxillary Labeling

Keep this and all other medications away from children and pets.

(Panthenol/ Hydroxocobalamin)

May be customized. customized.

Panthenol

Hydroxocobalamin

Possible Indications

Prophylactic use (immediately after major abdominal surgery) to minimize paralyticileus)

Treatment of pernicious anemia. Treatment of vitamin B12 deficiency due to dietary deficiencies or malabsorption diseases.

Possible Adverse Effects

Decreased blood pressure
Agitation
Paresthesia
Dermatitis
Pruritus
Skin irritation urticaria
Diarrhea
Increased peristalsis vomiting
Dyspnea
Hypersensitivity reaction

Pruritus
Skin rash
Anaphylaxis
Pain at injection site
Swelling (feeling of swelling of the entire body)
Increased blood pressure
Headache
Erythema
Nausea
Urine discoloration
Lymphocytopenia
Infusion site reaction
Chest discomfort
Peripheral edema
Dizziness
Memory impairment
Restlessness, Pruritus,
Urticaria
Hot flash
Abdominal distress
Diarrhea
Dyspepsia
Dysphagia
Hematochezia
Vomiting
Hypersensitivity reaction
Eye irritation; eye redness, swelling of eye
Dry throat
Dyspnea pharyngeal edema

Potential Contraindications/Precautions

Appropriate use: Management of adynamic ileus should include correction of fluid and electrolyte imbalance (especially hypokalemia), anemia, hypoproteinemia, treatment of infection, and the avoidance of drugs which decrease GI motility and decompression of the GI tract when considerably distended by nasogastric suction or use of a long intestinal tube. If ileus is a secondary consequence of mechanical obstruction, primary attention should be directed to the obstruction.

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Keep this and all other medications away from children and pets.

Pyrimethamine/Leucovorin* – Potential Ingredient Risks

(Pyrimethamine/Leucovorin)

May be customized.e customized.

Pyrimethamine

Leucovorin

Possible Indications

Used as an antimalarial and antiprotozoal agent: Toxoplasmosis, Cystoisosporiasis, Primary and Secondary Prophylaxis of Pneumocystis jiroveci Pneumonia. Has been used in the past for treatment of acute uncomplicated malaria.

Leucovorin is used as an antidote to diminish the toxicity and counteract the effect of unintentional overdosage of folic acid antagonists, such as methotrexate, trimethoprim, and pyrimethamine. Megaloblastic Anemia. Used to potentiate the antineoplastic activity of Fluorouracil for Advanced Colorectal Carcinoma.

Possible Adverse Effects

Anorexia
Abdominal cramps
Diarrhea
Vomiting
Ataxia
Tremors
Seizures
Occasionally severe sensitivity reactions

Allergic reactions to leucovorin may obscure the diagnosis of pernicious anemia.

Potential Contraindications/Precautions

Patients should be warned to keep pyrimethamine out of the reach of children. Children are extremely susceptible to adverse effects from an overdosage of pyrimethamine and accidental ingestion of pyrimethamine has been fatal in children. High dosages of pyrimethamine may deplete folic acid stores in patients receiving the drug and cause reversible bone marrow depression. Clinical studies of pyrimethamine did not include sufficient numbers of patients 65 years of age and older to determine whether geriatric patients respond differently than younger patients. Pyrimethamine has been shown to be teratogenic in rats, hamsters, and miniature pigs. Ref There are no adequate and controlled studies to date in humans. Pyrimethamine is distributed into milk. It is estimated that approximately 3–4 mg of the drug would be ingested by a nursing infant over the first 48-hour period following administration of a single 75-mg oral dose to the mother. Because of the potential for serious adverse reactions from pyrimethamine in nursing infants and from concurrent use of a sulfonamide with pyrimethamine for the treatment of toxoplasmosis, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

Animal reproduction studies have not been performed with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to pregnant women. Leucovorin should be used during pregnancy only when clearly needed. Since it is not known if leucovorin is distributed into milk, the drug should be used with caution in nursing women.

Storage

Store at Room Temperature 20°C to 25°C (68°F to 77°F).

Auxillary Labeling

Keep all medicine out of the reach of children and pets. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

PPS-DR* (pentosan polysulfate sodium delayed release) – Potential Ingredient Risks

(Pentosan Polysulfate Sodium)

May be customized.

Pentosan Polysulfate Sodium

Possible Indications

Symptomatic relief of bladder pain or discomfort associated with interstitial cystitis.

Possible Adverse Effects

Rectal hemorrhage and bleeding
Thrombocytopenia
Alopecia

Potential Contraindications/Precautions

Safety and efficacy of pentosan polysulfatesodium in pediatric patients younger than 16 years of age have not been established. Pentosan polysulfate sodium should be used with caution in patients with hepatic impairment. The drug has not been evaluated in this patient population. Because pentosan polysulfate sodium undergoes hepatic metabolism, hepatic impairment might alter the pharmacokinetics of the drug. It is not known whether pentosan polysulfate sodium is distributed into milk the drug should be used with caution in nursing women.

Storage

Store at Room Temperature 20°C to 25°C
(68°F to 77°F)

Auxillary Labeling

Keep all medicine out of the reach of children and pets. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

Tobramycin/Vancomycin ophthalmic solution* – Potential Ingredient Risks

(Tobramycin/Vancomycin)

Tobramycin

Vancomycin

Possible Indications

Treatment of infections of the eye
caused by susceptible bacteria

Possible Adverse Effects

Ocular burning/stinging on instillation
Lid itching and swelling
Conjunctival erythema
Anaphylactic reaction
Stevens-Johnson syndrome
Erythema multiforme
The following are adverse reactions reported
with systemic aminoglycosides:
– Neurotoxicity
– Ototoxicity
– Nephrotoxicity
– Aminoglycosides may aggravate muscle
weakness in patients with known
or suspected neuromuscular
disorders, such as myasthenia
gravis or Parkinson’s disease.

Ocular burning/stinging on instillation
Lid itching and swelling
Conjunctival erythema
Anaphylactic reaction
Stevens-Johnson syndrome
The following are adverse reactions
reported with systemic vancomycin
administration:
– Nephrotoxicity
– Onset of pseudomembranous
colitis symptoms
– Ototoxicity
– Neutropenia
Hemorrhagic occlusive retinal vasculitis
(HORV) may be associated with the use of
intraocular vancomycin (including
intravitreal, intracameral bolus, and
irrigating solution containing vancomycin).
Although the precise etiology of HORV
remains unproven, each surgeon should
weigh the potential risk of vancomycin
against the risk of endophthalmitis.

Potential Contraindications/Precautions

Patients Less than 12 Years
Nursing Mothers
Pregnancy

Storage

Store under refrigeration
2°C to 8°C (36°F to 46°F)

Auxillary Labeling

Protect from light

*Available from 503A only

Ordering from our FDA-Registered Outsourcing Facility? Order online today.

Ordering from our patient specific pharmacy? Prescribe today.

Ordering from our FDA-Registered Outsourcing Facility? Order online today.

Ordering from our patient specific pharmacy? Prescribe today.

Stay Informed